These innovative compounds represent a significant advancement in the treatment of type 2 diabetes. Retatrutide, a dual GLP-1 and GIP receptor agonist, demonstrates exceptional efficacy in reducing blood glucose https://alvinxflv287288.tinyblogging.com/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide-83103090